Large Cell Lung Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A poorly differentiated non-small cell lung carcinoma composed of large polygonal cells without evidence of glandular or squamous differentiation. There is a male predilection. 
Large cell lung carcinomas most frequently harbor alterations in TP53, STK11, KRAS, SMARCA4, and KEAP1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53 Exon 5 Mutation, and KRAS Mutation are the most common alterations in large cell lung carcinoma .
There are 2 clinical trials for large cell lung carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain large cell lung carcinoma as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
PD-L1 is the most frequent gene inclusion criterion for large cell lung carcinoma clinical trials .
Imu-201, nivolumab, and standard of care are the most common interventions in large cell lung carcinoma clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.